You are here:

linaclotide (Constella)

Advice

Following a full submission:

linaclotide (Constella®) is accepted for restricted use within NHS Scotland.

Indication under review: symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults.

SMC restriction: linaclotide is restricted for use in patients with moderate to severe IBS-C who have not responded adequately to or cannot tolerate all other suitable treatment options.

In two pivotal phase III studies linaclotide was superior to placebo for the co-primary endpoints of abdominal pain/discomfort responders and IBS degree-of-relief responders at 12 weeks. There are no comparative efficacy data versus first- or second-line treatments.

Drug Details

Drug Name: linaclotide (Constella)
SMC Drug ID: 869/13
Manufacturer: Almirall Ltd
Indication: For the symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults.
BNF Category:
Sub Category: 1.5 Chronic bowel disorders
Submission Type: Full submission
Status: Restricted
Date Advice Published: 10 June 2013

Back